We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024
25 Apr 2024 - 27 Apr 2024

Breakthrough Test Detects Biological Markers Related to Wider Variety of Cancers

By LabMedica International staff writers
Posted on 21 Apr 2023
Print article
Image: A new test detects biological markers related to several types of cancer (Photo courtesy of Freepik)
Image: A new test detects biological markers related to several types of cancer (Photo courtesy of Freepik)

When assessing potential cancer cases, physicians rely on biomarker tests to aid in diagnosis. These tests, utilizing a testing system and patient samples, enable doctors to explore possible indicators and narrow down their search for the most accurate and effective treatment. Now, researchers have devised a novel test to identify biological markers associated with various cancer types.

A team of chemists at Florida State University (Tallahassee, FL, USA) has created a sensing platform made of a gold nanoparticle and dye-labeled peptide molecules. These components are linked by chemical bonds, with the gold nanoparticle preventing the dye from emitting light under UV exposure. When a patient sample containing the enzyme MMP-14 – a biomarker for multiple cancer types, most commonly breast cancer – is introduced, it breaks the peptide bonds, separating the dye-containing fragment from the gold. In the absence of gold to absorb the dye's energy, the sample starts to emit light. The intensity of this light emission depends on the enzyme concentration and interaction duration. By analyzing this light, researchers can determine the presence and levels of a cancer marker in the sample.

Although there are already numerous tests to identify cancer in patients, this research represents an initial step towards developing a method capable of detecting a broader range of cancers. The research team has tested their system with the MMP-14 enzyme but intends to expand their efforts by pairing more peptide chains with other enzyme cancer markers. This advancement could eventually enable scientists to use a single test to simultaneously screen for various cancers. In addition to its diagnostic applications, the study also provides further insights into enzyme interactions with peptide-bound nanoparticles and the impact of enzyme addition on the testing system.

“Better tools for detecting cancer mean more effective treatment for patients,” said study co-author Hedi Mattoussi, a professor in the FSU Department of Chemistry and Biochemistry. “Our goal in this research was to build a biosensor that would light up in the presence of cancer markers, offering another tool for the ongoing problem of detecting this disease.”

Related Links:
Florida State University 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Plasma Control
Plasma Control Level 1

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: AI analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer (Photo courtesy of Adobe Stock)

Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer

Ovarian cancer is one of the most common causes of cancer deaths among women and has a five-year survival rate of around 50%. The disease is particularly lethal because it often doesn't cause symptoms... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more


view channel
Image: ‘Virtual biopsy’ allows clinicians to analyze skin noninvasively (Photo courtesy of Stanford Medicine)

Virtual Skin Biopsy Determines Presence of Cancerous Cells

When dermatologists spot an unusual mark on a patient's skin, they face a choice: monitor it for some time or remove it for biopsy. Similarly, when removing breast tumors, surgeons must send excised tissues... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.